I. Poizot-Martin

发表

Acute and chronic hepatitis E in patients infected with human immunodeficiency virus

P. Colson, C. Dhiver, C. Tamalet, 2011, Journal of viral hepatitis.

Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).

L. Cuzin, Y. Lévy, O. Launay, 2013, Vaccine.

Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART).

Roch Giorgi, Camelia Protopopescu, M. Carrieri, 2009, Drug and alcohol dependence.

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

M. Carrieri, B. Spire, I. Poizot-Martin, 2008, Addiction.

[Cutaneo-mucosal hyperpigmentation in AIDS. 4 cases].

R. Bouabdallah, C. Dhiver, I. Poizot-Martin, 1991, Presse medicale.

Discrepancy between Blood and Cerebral Didanosine Effects in HIV Patients: A Magnetic Resonance Spectroscopy Study

J. Vion-Dury, I. Poizot-Martin, J. Gastaut, 2005, European Neurology.

Baseline CD4 Cell Count and Outcome of Pegylated Interferon Plus Ribavirin Therapy in HIV/Hepatitis C Virus-Coinfected Patients

K. Freedberg, Y. Yazdanpanah, A. Tran, 2008, Journal of acquired immune deficiency syndromes.

[CCR5-antagonists: contribution of a new antiretroviral class to the management of HIV infection].

I. Poizot-Martin, 2010, Medecine et maladies infectieuses.

Efficacy and Tolerability of a Nucleoside Reverse Transcriptase Inhibitor-Sparing Combination of Lopinavir/Ritonavir and Efavirenz in HIV-1-Infected Patients

F. Raffi, C. Michelet, C. Brunet-François, 2005, Journal of acquired immune deficiency syndromes.

Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4

D. Costagliola, Y. Lévy, C. Pradier, 2009, Journal of acquired immune deficiency syndromes.

Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription

C. Katlama, Y. Yazdanpanah, L. Cuzin, 2012, International journal of STD & AIDS.

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

O. Rouvière, I. Poizot-Martin, J. Lang, 1999, AIDS.

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study

O. Rouvière, I. Poizot-Martin, J. Lang, 2000, AIDS.

Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition

S. Grabar, J. Spano, C. Solas, 2021, Cancers.

Risk factors associated with overweight and obesity in HIV-infected people

S. Brégigeon, I. Poizot-Martin, C. Lions, 2018, Medicine.

Risk factors of chronic kidney disease in HIV-infected patients.

C. Katlama, Y. Yazdanpanah, L. Cuzin, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Risk Factors of Chronic Kidney Disease in

C. Katlama, Y. Yazdanpanah, L. Cuzin, 2011 .

HIV-1 Infection and First Line ART Induced Differential Responses in Mitochondria from Blood Lymphocytes and Monocytes: The ANRS EP45 “Aging” Study

N. Lévy, J. Micallef, E. Jouve, 2012, PloS one.

Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial.

A. Desnoyer, D. Costagliola, C. Lebbé, 2016, AIDS research and human retroviruses.

The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010

D. Neau, P. Morlat, F. Dabis, 2010, BMC infectious diseases.

All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.

D. Neau, P. Morlat, F. Dabis, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Distribution of human papillomavirus genotypes, assessment of HPV 16 and 18 viral load and anal related lesions in HIV positive patients: A cross‐sectional analysis

S. Brégigeon, C. Tamalet, I. Poizot-Martin, 2014, Journal of medical virology.

Wildo Navegantes de Araújo, M. Ziol, V. Paradis, 2019, AIDS and Behavior.

ITPA Deficiency and Ribavirin Level are Still Predictive of Anaemia in HCV–HIV-Coinfected Patients Receiving Ribavirin Combined with a First-Generation DAA (ANRS HC27 Study)

C. Solas, B. Lacarelle, É. Bellissant, 2016, Antiviral therapy.

Intensive sequential chemotherapy with hematopoietic growth factor support for non‐Hodgkin lymphoma in patients infected with the human immunodeficiency virus

L. Xerri, D. Olive, V. Bardou, 2004, Cancer.

A Case of Undiagnosed HIV Infection in a 57-Year-Old Woman with Multiple Myeloma: Consequences on Chemotherapy Efficiency and Safety

R. Bouabdallah, C. Solas, S. Brégigeon, 2016, Case reports in oncological medicine.

A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients

P. Morlat, F. Raffi, C. Michelet, 1997, AIDS.

Phase IV Study of Liposomal Daunorubicin (DaunoXome) in AIDS-Related Kaposi Sarcoma

J. Spano, P. Cacoub, I. Poizot-Martin, 2002, American journal of clinical oncology.

Spectrum and Incidence Trends of AIDS- and Non–AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort

S. Brégigeon, P. Delobel, A. Frésard, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Prevalence and Spectrum of Second Primary Malignancies among People Living with HIV in the French Dat’AIDS Cohort

C. Delpierre, S. Brégigeon, P. Delobel, 2022, Cancers.

Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).

S. Chevret, V. Bourcier, J. Trinchet, 2012, Clinics and research in hepatology and gastroenterology.

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis

F. Brun-Vézinet, W. Rozenbaum, D. Costagliola, 2014, Journal of the International AIDS Society.

T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial

B. Hejblum, F. Lucht, J. Lelièvre, 2022, The Journal of Immunology.

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)

M. Carrieri, C. Protopopescu, T. Barré, 2021, Expert review of anti-infective therapy.

Frailty in HIV infected people: a new risk factor for bone mineral density loss

A. Galinier, S. Brégigeon, I. Poizot-Martin, 2017, AIDS.

A Randomized, Double-Blind, Placebo-Controlled Study of Benfluorex in HIV-Infected Patients with Insulin Resistance or Impaired Glucose Tolerance

E. Jouve, I. Poizot-Martin, J. Gastaut, 2009 .

Risk of diabetes in HIV‐infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort

L. Cuzin, F. Raffi, M. Dramé, 2018, Alimentary pharmacology & therapeutics.

Visceral leishmaniasis and HIV-1 co-infection in southern France.

F. Pratlong, O. Boulat, J. Dereure, 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Endothelial cell dysfunction in HIV infection.

C. Tamalet, C. Zandotti, I. Poizot-Martin, 1992, Journal of acquired immune deficiency syndromes.

Do people living with HIV face more secondary cancers than general population: From the French CANCERVIH network.

C. Katlama, D. Costagliola, J. Spano, 2021, Bulletin du cancer.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort

C. Katlama, D. Neau, P. Morlat, 2018, PLoS ONE.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort

C. Katlama, D. Neau, P. Morlat, 2018, PloS one.

Protein S deficiency and HIV infection.

C. Dhiver, I. Poizot-Martin, I. Juhan-vague, 1991, The New England journal of medicine.

Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network.

C. Katlama, J. Spano, P. Perre, 2019, AIDS.

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma

J. Spano, C. Solas, S. Brégigeon, 2022, Cancers.

Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients

D. Neau, P. Sogni, A. Gervais, 2019, Journal of acquired immune deficiency syndromes.

Efficacy and Tolerance of HCV Treatment in HIV-HCV Coinfected Patients: The Potential Interaction of PI Treatment

C. Tamalet, I. Poizot-Martin, C. Marimoutou, 2003, HIV clinical trials.

HIV is associated with airway obstruction: a matched controlled study

M. Zins, S. Eymard-Duvernay, F. Raffi, 2017, AIDS.

HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

M. Ziol, C. Delaugerre, C. Katlama, 2022, AIDS Research and Therapy.

In situ expression of the IL-1-alpha and TNF-alpha genes by Reed-Sternberg cells in Hodgkin's disease.

R. Bouabdallah, F. Birg, L. Xerri, 1992, International journal of cancer.

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy

C. Solas, B. Lacarelle, É. Bellissant, 2016, AIDS.

Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma.

J. Rey, I. Poizot-Martin, R. Costello, 2003, AIDS.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

V. de Lédinghen, D. Neau, P. Morlat, 2019, PloS one.

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients

C. Katlama, P. Morlat, F. Dabis, 2018, World journal of hepatology.

Ledipasvir and tenofovir drug interaction in human immunodeficiency virus–hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety

C. Solas, S. Brégigeon, C. Tamalet, 2018, British journal of clinical pharmacology.

Renal Impairment in Patients Receiving a Tenofovir-cART Regimen: Impact of Tenofovir Trough Concentration

C. Solas, S. Brégigeon, B. Lacarelle, 2013, Journal of acquired immune deficiency syndromes.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Nelfinavir in HIV-HCV coinfected patients: a 24-month follow-up in a cohort of 82 patients.

I. Poizot-Martin, C. Marimoutou, J. Gastaut, 2005, AIDS research and human retroviruses.

Prise en charge de l'infection à VIH en 2005 en France à travers 7416 patients de la cohorte NADIS

L. Cuzin, I. Poizot-Martin, Y. Yazdanpanah, 2006 .

Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.

M. Carrieri, B. Spire, I. Poizot-Martin, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

F. Zoulim, L. Cuzin, B. Hoen, 2017, BMC Medicine.

Effects of antiretroviral drug combinations on the differentiation of adipocytes

R. Roche, E. Compe, I. Poizot-Martin, 2002, AIDS.

High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen.

C. Solas, B. Lacarelle, I. Poizot-Martin, 2002, Journal of acquired immune deficiency syndromes.

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

T. Allègre, C. Solas, C. Dhiver, 2004, British journal of clinical pharmacology.

Tolerance and Durability of Abacavir/Lamivudine (Abc/3tc) Containing Regimens: Results from a large French Prospective Cohort

H. Melliez, L. Cuzin, I. Poizot-Martin, 2012 .

CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART

L. Cuzin, B. Hoen, I. Poizot-Martin, 2016, PloS one.

Increased interleukin-6 production is associated with disease progression in HIV infection.

J. Mege, P. Bongrand, C. Farnarier, 1991, AIDS.

The spectrum of malignancies in HIV‐infected patients in 2006 in France: The ONCOVIH study

É. Oksenhendler, G. Carcelain, H. Agut, 2011, International journal of cancer.

Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy

D. Costagliola, C. Dhiver, M. Mary-Krause, 2006, AIDS.

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor

D. Costagliola, S. Grabar, P. Fabbro-Péray, 2000, AIDS.

CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies.

A. Winston, P. Reiss, M. Guiguet, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Frequency, determinants and consequences of delayed access to care for HIV infection in France

E. Lanoy, D. Costagliola, M. Mary-Krause, 2007, Antiviral therapy.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Epidemiological and virological features of HBV infection in HIV-2 infected patients living in southeastern France

P. Colson, C. Tamalet, I. Poizot-Martin, 2006, European Journal of Epidemiology.

Sub-therapeutic darunavir concentration and garlic consumption; a «Mediterranean» drug-food interaction, about 2 cases

C. Solas, S. Brégigeon, I. Poizot-Martin, 2017, European Journal of Clinical Pharmacology.

Hepatitis E virus infection in patients infected with the human immunodeficiency virus

P. Brouqui, H. Richet, P. Colson, 2011, Journal of medical virology.

Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome.

P. Colson, C. Tamalet, I. Poizot-Martin, 2006, Journal of Clinical Virology.

Ribavirin and abacavir drug interaction in HIV–HCV coinfected patients: fact or fiction?

J. Izopet, C. Solas, G. Peytavin, 2012, AIDS.

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study

P. Pradat, J. Parienti, L. Cotte, 2017, PloS one.

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).

P. Morlat, W. Rozenbaum, G. Chêne, 2011, The Journal of antimicrobial chemotherapy.

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.

P. Morlat, W. Rozenbaum, F. Collin, 2005, The Journal of infectious diseases.

Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial

C. Pradier, I. Poizot-Martin, P. Dellamonica, 2010, AIDS care.

Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials: a French cohort study.

L. Cuzin, S. Grabar, B. Spire, 2019, AIDS.

Long-term persistence of vaccine-induced HIV seropositivity in healthy volunteers.

L. Cuzin, J. Lelièvre, B. Silbermann, 2014 .

Long-Term Persistence of Vaccine-Induced HIV Seropositivity in Healthy

L. Cuzin, J. Lelièvre, B. Silbermann, 2014 .

First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.

C. Katlama, C. Delpierre, L. Cuzin, 2016, Medicine.

Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years.

C. Tamalet, F. Dignat-George, I. Poizot-Martin, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.

P. Colson, C. Solas, S. Brégigeon, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients

David Rey, L. Cuzin, P. Pradat, 2015, PloS one.

The Genotypic Inhibitory Quotient: A Predictive Factor of Atazanavir Response in HIV-1-Infected Treatment-Experienced Patients

P. Colson, C. Solas, C. Tamalet, 2008, Journal of acquired immune deficiency syndromes.

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France

P. Brouqui, A. Stein, P. Colson, 2014, Journal of medical virology.

Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France

P. Colson, S. Mokhtari, C. Tamalet, 2015, Journal of medical virology.

Genomic and phylogenetic analysis of hepatitis C virus isolates: A survey of 535 strains circulating in southern France

P. Colson, C. Tamalet, I. Poizot-Martin, 2003, Journal of medical virology.

Use of first‐generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1

S. Pol, P. Cacoub, G. Pialoux, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV–HCV co‐infected patients: ANRS Co13 Hepavih, France, 2006–2008

F. Dabis, M. Carrieri, B. Spire, 2009, Journal of viral hepatitis.

Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.

C. Solas, B. Lacarelle, I. Poizot-Martin, 2002, Journal of acquired immune deficiency syndromes.

L. Quéro, G. Carcelain, C. Katlama, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers

S. Eymard-Duvernay, F. Raffi, F. Bonnet, 2016, AIDS.

HHV-8 in PBMC and kaposi's sarcoma activity

I. Poizot-Martin, A. Lafeuillade, C. Poggi, 1997, Infection.

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

A. LaMarca, B. Clotet, C. Katlama, 2012, The Journal of infectious diseases.

Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.

D. Costagliola, M. Mary-Krause, I. Poizot-Martin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study

L. Cuzin, J. Pujol, S. Eymard-Duvernay, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cellular Immune Responses Induced with Dose-Sparing Intradermal Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial

L. Cuzin, J. Guillet, B. Silbermann, 2007, PloS one.

Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial

Yves Lévy, Jean-Pierre Aboulker, L. Cuzin, 2010, AIDS.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen

C. Katlama, B. Hoen, F. Raffi, 2017, The Journal of antimicrobial chemotherapy.

Life after hepatitis C cure in HIV‐infected people who inject drugs and men who have sex with men treated with direct‐acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH)

P. Carrieri, M. Mora, P. Sogni, 2020, Journal of viral hepatitis.

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, BMC Infectious Diseases.

Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era.

H. Cubie, C. Moore, D. Costagliola, 2016, The Journal of infectious diseases.

Mandibular osteonecrosis and dental exfoliation after trigeminal zoster in an HIV-infected patient: case report and review of the literature.

S. Brégigeon, C. Chossegros, I. Poizot-Martin, 2014, AIDS.

A large French prospective cohort of HIV‐infected patients: the Nadis Cohort

L. Cuzin, M. Valantin, I. Poizot-Martin, 2009, HIV medicine.

Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV

B. Hoen, F. Raffi, P. Pradat, 2018, AIDS.

Kaposi sarcoma in people living with HIV: incidence and associated factors in the French DAT'AIDS cohort between 2010 and 2015.

I. Poizot-Martin, A. Chéret, D. Rey, 2019, AIDS.

Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group

B. Milleron, J. Pujol, J. Spano, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France

M. Carrieri, C. Protopopescu, P. Delobel, 2022, PloS one.

HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.

J. Goedert, P. Rosenberg, E. Lanoy, 2011, Blood.

Incidence o f N on-AIDS-Definin g C ancers B efore a nd D uring the H ighly A ctive A ntiretroviral T herapy E ra i n a C ohort o f Human I mmunodeficiency V irus-Infected P atients

D. Costagliola, M. Mary-Krause, I. Poizot-Martin, 2003 .

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

D. Neau, P. Morlat, F. Dabis, 2017, Journal of hepatology.

Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018.

C. Charpentier, R. Tubiana, C. Katlama, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?

L. Cuzin, B. Hoen, P. Pradat, 2017, The Journal of infection.

Hepatitis C treatment initiation in HIV-HCV coinfected patients

L. Cuzin, P. Pradat, L. Cotte, 2016, BMC Infectious Diseases.

Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.

V. de Lédinghen, V. Paradis, B. Autran, 2020, Journal of hepatology.

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients

C. Katlama, F. Raffi, M. Hanf, 2018, PloS one.

Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)‐coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]

D. Neau, P. Morlat, B. Spire, 2016, HIV medicine.

Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia.

C. Katlama, D. Costagliola, J. Spano, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy

S. Brégigeon, C. Tamalet, F. Dignat-George, 2015, AIDS.

Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients

C. Katlama, B. Hoen, F. Raffi, 2016, Infectious diseases.

High Prevalence of Anal Human Papillomavirus-Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women.

H. Cubie, C. Moore, D. Costagliola, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).

C. Katlama, M. Guiguet, D. Costagliola, 2014, International journal of epidemiology.

Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM

L. Siproudhis, G. Clifford, J. Fléjou, 2018, AIDS.

Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).

M. Ziol, V. Paradis, C. Delaugerre, 2020, Journal of hepatology.

Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit

P. Carrieri, C. Solas, S. Brégigeon, 2019, European journal of gastroenterology & hepatology.

Determinants and evolution of squamous intraepithelial lesions in HIV-infected women, 1991–2004

I. Poizot-Martin, P. Cau, A. Robaglia-Schlupp, 2007, AIDS care.

Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correction: HIV Protease Inhibitors Do Not Cause the Accumulation of Prelamin A in PBMCs from Patients Receiving First Line Therapy: The ANRS EP45 “Aging” Study

N. Lévy, J. Micallef, C. Solas, 2013, PLoS ONE.

HIV Protease Inhibitors Do Not Cause the Accumulation of Prelamin A in PBMCs from Patients Receiving First Line Therapy: The ANRS EP45 “Aging” Study

N. Lévy, J. Micallef, C. Solas, 2012, PloS one.

Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH With HIV-Controlled Disease Treated for Solid Malignancies: A DAT’AIDS Study

I. Poizot-Martin, L. Hocqueloux, V. Joly, 2022, Open forum infectious diseases.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).

V. Calvez, D. Podzamczer, C. Delaugerre, 2020, The Journal of antimicrobial chemotherapy.

Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.

F. Dabis, F. Raffi, M. Carrieri, 2017, Journal of hepatology.

Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).

F. Dabis, M. Carrieri, B. Spire, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.

D. Costagliola, Y. Lévy, C. Pradier, 2010, The Journal of antimicrobial chemotherapy.

Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048–079 Trials)*

É. Oksenhendler, Y. Lévy, C. Goujard, 2007, AIDS.

Missed opportunities for HIV pre‐exposure prophylaxis among people with recent HIV infection: The French ANRS 95041 OMaPrEP study

B. Spire, G. Maradan, M. Mora, 2022, HIV medicine.

Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus–Positive Men Who Have Sex with Men

V. Pialoux, L. Siproudhis, G. Clifford, 2018, The Journal of infectious diseases.

Incidence and clearance of anal HPV-16 and HPV-18 infection, and their determinants, among HIV-infected men who have sex with men in France.

L. Siproudhis, C. J. Alberts, G. Clifford, 2019, The Journal of infectious diseases.

Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC)

P. Morlat, F. Raffi, B. Spire, 2017, PloS one.

False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers.

É. Oksenhendler, C. Katlama, D. Neau, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Unsupervised PrEP in routine practice: a new challenge?

C. Tamalet, I. Poizot-Martin, C. Lions, 2019, International journal of STD & AIDS.

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

P. Carrieri, P. Colson, C. Solas, 2016, HIV clinical trials.

Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations.

J. Fantini, P. Colson, C. Dhiver, 2000, Virology.

Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV‐1 infection

P. Massip, C. Pasquier, J. Puel, 2000, Journal of medical virology.

Survival after neuroAIDS

D. Costagliola, C. Dhiver, I. Poizot-Martin, 2011, Neurology.

Extracellular vesicles from T cells overexpress miR-146b-5p in HIV-1 infection and repress endothelial activation

J. Micallef, F. Dignat-George, I. Poizot-Martin, 2019, Scientific Reports.

Factors associated with deaths from suicide in a French nationwide HIV‐infected cohort

M. Dramé, M. Valantin, A. Kaladjian, 2018, HIV medicine.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials)

M. Carrieri, L. Cotte, I. Poizot-Martin, 2016, European journal of gastroenterology & hepatology.

An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy

C. Delaugerre, C. Delpierre, L. Cuzin, 2013, HIV medicine.

HIV infection and care pathway: From guidelines to clinical practice.

S. Brégigeon, I. Poizot-Martin, C. Lions, 2019, Medecine et maladies infectieuses.

Impact of Tenofovir dose Adjustment on Both Estimated Glomerular Filtration Rate and Tenofovir trough Concentration

C. Solas, S. Brégigeon, C. Tamalet, 2017, Antiviral therapy.

5-Fluoro-uracil-clindamycin for treatment of cerebral toxoplasmosis.

C. Dhiver, I. Poizot-Martin, J. Gastaut, 1993, AIDS.

Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.

Laurent Tran, L. Meyer, P. Delobel, 2019, AIDS.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France

Y. Yazdanpanah, C. Delpierre, L. Cuzin, 2018, HIV medicine.

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study

F. Raffi, M. Dramé, P. Delobel, 2016, Medicine.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

C. Protopopescu, B. Spire, M. Préau, 2006, Revue d'epidemiologie et de sante publique.

Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus.

C. Katlama, D. Neau, P. Morlat, 2020, Clinical Infectious Diseases.

Changes in the Profile and Care of HIV-HCV Seropositive Patients in TwoCross-Sectional Surveys in France (2006 and 2013)

P. Morlat, S. Pol, P. Cacoub, 2014 .

High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients.

C. Tamalet, I. Poizot-Martin, M. Henry, 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.

C. Michelet, D. Guyader, P. Perre, 2013, The Journal of infection.

Emergence of uncommon HIV‐1 non‐B subtypes and circulating recombinant forms and trends in transmission of antiretroviral drug resistance in patients with primary infection during the 2013‐2015 period in Marseille, Southeastern France

P. Brouqui, A. Stein, P. Colson, 2018, Journal of medical virology.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

C. Katlama, Y. Yazdanpanah, C. Blanco-Betancourt, 2017, HIV medicine.

Extracellular vesicles from T cells overexpress miR-146b-5p in HIV-1 infection and repress endothelial activation

J. Micallef, F. Dignat-George, I. Poizot-Martin, 2019, Scientific Reports.

Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people.

Y. Yazdanpanah, C. Delpierre, L. Cuzin, 2008, European journal of public health.

Short article: Fatigue in the long term after HCV treatment in HIV–HCV-coinfected patients functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort)

F. Dabis, M. Carrieri, C. Protopopescu, 2016, European journal of gastroenterology & hepatology.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.

C. Katlama, D. Neau, P. Morlat, 2019, European journal of gastroenterology & hepatology.

Zidovudine overdose: a case with bone-marrow toxicity.

R. Bouabdallah, C. Dhiver, I. Poizot-Martin, 1991, AIDS (London).

Are CD4 antibodies and peptide T new treatments for psoriasis?

D. Olive, C. Dhiver, I. Poizot-Martin, 1991, The Lancet.

Can the “Seek, Test, Treat, and Retain” Strategy be Effective in France?

Y. Yazdanpanah, L. Cuzin, B. Hoen, 2013, Journal of acquired immune deficiency syndromes.

[Demographic, clinical, immunovirological and therapeutic features of 8714 HIV infected French patients included in the Nadis Hospital Cohorte in 2006].

Y. Yazdanpanah, L. Cuzin, I. Poizot-Martin, 2008, Medecine et maladies infectieuses.

Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort

M. Ziol, C. Delaugerre, C. Katlama, 2020 .

Diet‐induced thermogenesis in HIV infection

I. Poizot-Martin, P. Philibert, J. Boulet, 1994, AIDS.

Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.

C. Katlama, Y. Lévy, C. Solas, 2012, The Journal of antimicrobial chemotherapy.

Ageing with HIV: do comorbidities and polymedication drive treatment optimization?

C. Katlama, L. Cuzin, L. Cotte, 2017, HIV medicine.

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

L. Cuzin, L. Cotte, I. Poizot-Martin, 2017, PloS one.

Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.

Alain Durand, Nicolas Simon, Bruno Lacarelle, 2007, British journal of clinical pharmacology.

Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

V. de Lédinghen, Y. Yazdanpanah, D. Neau, 2018, HIV medicine.

Efficacy , safety and patient-reported outcomes of ledipasvir / sofosbuvir in NS 3 / 4 A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis ( ANRS HC 31 SOFTRIH study )

M. Dupon, P. Morlat, T. Allègre, 2019 .

Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING

B. Spire, I. Poizot-Martin, V. Jullien, 2017, HIV clinical trials.

Daclatasvir Plasma Concentration Assessment in HIV–HCV-Coinfected Real-Life Patients

P. Colson, C. Solas, C. Dhiver, 2017, Antiviral therapy.

Ledipasvir and Tenofovir drug interaction in HIV‐HCV co‐infected patients: Impact on Tenofovir Ctrough and Renal Safety

C. Solas, S. Brégigeon, C. Tamalet, 2017 .

Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

M. Ziol, C. Delaugerre, C. Katlama, 2022, JHEP reports : innovation in hepatology.

Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.

C. Katlama, P. Muret, C. Solas, 2012, The Journal of antimicrobial chemotherapy.

Determinants of Second Primary Cancer Type in Survivors of Virus-Related and Non-Virus-Related Cancer Living With HIV in the French Dat’AIDS Cohort

C. Delpierre, S. Brégigeon, P. Delobel, 2021, Cancer control : journal of the Moffitt Cancer Center.

No increased risk of Kaposi sarcoma relapse in patients with controlled HIV‐1 infection after switching protease inhibitor‐based antiretroviral therapy

C. Delpierre, L. Cuzin, G. Martin-Blondel, 2021, HIV medicine.

Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort

H. Melliez, L. Cuzin, F. Raffi, 2012, Scandinavian journal of infectious diseases.

Factors associated with being overweight and obesity in people living with HIV on antiretroviral therapy : socio-clinical, inflammation, and metabolic markers.

A. Maignan, Y. Yazdanpanah, D. Neau, 2021, The Journal of infectious diseases.